In an AD mouse model, it decreased the levels of microglial Tmem9 to inhibit the activation of complement, alleviated complement‐dependent synaptic loss, and eventually ameliorated emotional and cognitive disorders. The gene discussed is TMEM9; the disease is cognitive disorder.